Review article · 2023 · Open access
CAR T cells for treating autoimmune diseases
RMD Open, 9(4), e002907 · Published 1 November 2023 · DOI 10.1136/rmdopen-2022-002907
In brief
“CAR T cells for treating autoimmune diseases” is a 2023 review article by Ulrich Blache and 4 co-authors, published in RMD Open. OpenAlex counts 104 citations as of 19 November 2026, which puts it in the top 1% of works published in 2023 by citations. It is open access under a CC BY-NC licence: the full text is free to read at RMD Open.
- Citations
- 104
- Most cited in
- 2025 (47)
- Field-weighted impact
- 3.16
- References
- 60
- Authors
- 5
Abstract
Autoimmune disorders occur when immune cells go wrong and attack the body's own tissues. Currently, autoimmune disorders are largely treated by broad immunosuppressive agents and blocking antibodies, which can manage the diseases but often are not curative. Thus, there is an urgent need for advanced therapies for patients suffering from severe and refractory autoimmune diseases, and researchers have considered cell therapy as potentially curative approach for several decades. In the wake of its success in cancer therapy, adoptive transfer of engineered T cells modified with chimeric antigen receptors (CAR) for target recognition could now become a therapeutic option for some autoimmune diseases. Here, we review the ongoing developments with CAR T cells in the field of autoimmune disorders. We will cover first clinical results of applying anti-CD19 and anti-B cell maturation antigen CAR T cells for B cell elimination in systemic lupus erythematosus, refractory antisynthetase syndrome and myasthenia gravis, respectively. Furthermore, in preclinical models, researchers have also developed chimeric autoantibody receptor T cells that can eliminate individual B cell clones producing specific autoantibodies, and regulatory CAR T cells that do not eliminate autoreactive immune cells but dampen their wrong activation. Finally, we will address safety and manufacturing aspects for CAR T cells and discuss mRNA technologies and automation concepts for ensuring the future availability of safe and efficient CAR T cell products.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Blache, U., Tretbar, S., Koehl, U., Mougiakakos, D., & Fricke, S. (2023). CAR T cells for treating autoimmune diseases. RMD Open, 9(4), e002907. https://doi.org/10.1136/rmdopen-2022-002907
MLA 9
Blache, Ulrich, et al. “CAR T cells for treating autoimmune diseases.” RMD Open, vol. 9, no. 4, 2023, p. e002907. https://doi.org/10.1136/rmdopen-2022-002907.
Chicago
Blache, Ulrich, Sandy Tretbar, Ulrike Koehl, Dimitrios Mougiakakos, and Stephan Fricke. 2023. “CAR T cells for treating autoimmune diseases.” RMD Open 9 (4): e002907. https://doi.org/10.1136/rmdopen-2022-002907.
Harvard
Blache, U. et al. (2023) ‘CAR T cells for treating autoimmune diseases’, RMD Open, 9(4), p. e002907. doi:10.1136/rmdopen-2022-002907.
IEEE
U. Blache, S. Tretbar, U. Koehl, D. Mougiakakos, and S. Fricke, “CAR T cells for treating autoimmune diseases,” RMD Open, vol. 9, no. 4, p. e002907, 2023, doi: 10.1136/rmdopen-2022-002907.
BibTeX
@article{blache2023cells,
title = {{CAR T cells for treating autoimmune diseases}},
author = {Blache, Ulrich and Tretbar, Sandy and Koehl, Ulrike and Mougiakakos, Dimitrios and Fricke, Stephan},
journal = {RMD Open},
year = {2023},
volume = {9},
number = {4},
pages = {e002907},
doi = {10.1136/rmdopen-2022-002907},
url = {https://doi.org/10.1136/rmdopen-2022-002907}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2024 | 30 | |
| 2025 | 47 | |
| 2026 | 27 |
Its field-weighted citation impact is 3.16: it has been cited 3.16 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- chimeric antigen receptor T cells
- autoimmune disease
- chimeric antigen receptor
- systemic lupus erythematosus
- anti-CD19
- antisynthetase syndrome
- myasthenia gravis
- autoreactive B cells
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Blache, U., Tretbar, S., Koehl, U., Mougiakakos, D., & Fricke, S. (2023). CAR T cells for treating autoimmune diseases. RMD Open, 9(4), e002907. https://doi.org/10.1136/rmdopen-2022-002907
How many times has this paper been cited?
104 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at RMD Open: sign in and open the PDF from this page.
Who wrote this paper?
Ulrich Blache, Sandy Tretbar, Ulrike Koehl, Dimitrios Mougiakakos, Stephan Fricke.
What is the DOI of this paper?
10.1136/rmdopen-2022-002907, permanently at https://doi.org/10.1136/rmdopen-2022-002907. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.